Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Katalin Csermak Renner"'
Autor:
Samantha Akakpo, James S. McCarthy, Elhadj Djeriou, Katalin Csermak-Renner, G. Dennis Shanks, Didier Leboulleux, Anand Odedra, Cornelis Winnips, Mohamed Farouk Chughlay, Aditya H. Gaur, Stephan Chalon
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 103:378-393
Malaria volunteer infection studies (VISs) accelerate new drug and vaccine development. In the induced blood-stage malaria (IBSM) model, volunteers are inoculated with erythrocytes infected with Plasmodium falciparum. Observations of elevated liver e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a60fbd9269ca557db19b46f21e0eb46c
https://doi.org/10.4269/ajtmh.19-0846
https://doi.org/10.4269/ajtmh.19-0846
Autor:
Adoke Yeka, Judith Straimer, Guoqin Su, Martin P. Grobusch, Kwaku Poku Asante, Vinay Kumar Venishetty, Sarfaraz Sayyed, Stephen Asiimwe, Gilles F. Ndayisaba, Sarita Barsainya, Abraham Oduro, Caroline Boulton, Henry Mugerwa, Esther K. Schmitt, Etienne Karita, Katalin Csermak Renner, Seydou Doumbia, P. Gandhi, Ivan Demin, Bakary Fofana
Publikováno v:
Clinical infectious diseases. Oxford University Press
Background Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses. These were secondary endpoints from a study primarily conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::976d24df7b3925eb85fe952adea3a862
https://pubmed.ncbi.nlm.nih.gov/34410358
https://pubmed.ncbi.nlm.nih.gov/34410358
Publikováno v:
The Journal of infectious diseases. 225(8)
In Southeast Asia, mutations in the Plasmodium falciparum K13 gene have led to delayed parasite clearance and treatment failures in patients with malaria receiving artemisinin combination therapies. Until recently, relevant K13 mutations had been mos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb53b00f9a1635add9e1d40ec215cdb3
https://pubmed.ncbi.nlm.nih.gov/34216470
https://pubmed.ncbi.nlm.nih.gov/34216470
Autor:
J. Prakash Jain, Azrin N Abd-Rahman, Paul M. Griffin, Katharine A. Collins, Cornelis Winnips, Katalin Csermak-Renner, Anne Kümmel, James S. McCarthy, P. Gandhi, Vishal Mishra, Aline Fuchs, Louise Marquart
Publikováno v:
Antimicrobial Agents and Chemotherapy
The spiroindolone cipargamin, a new antimalarial compound that inhibits Plasmodium ATP4, is currently in clinical development. This study aimed to characterize the antimalarial activity of cipargamin in healthy volunteers experimentally infected with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e96f74ddf7ba88577a0b7e1e2828ea
https://doi.org/10.1128/aac.01423-20
https://doi.org/10.1128/aac.01423-20
Autor:
Mohamed Farouk, Chughlay, Samantha, Akakpo, Anand, Odedra, Katalin, Csermak-Renner, Elhadj, Djeriou, Cornelis, Winnips, Didier, Leboulleux, Aditya H, Gaur, G Dennis, Shanks, James, McCarthy, Stephan, Chalon
Publikováno v:
The American Journal of Tropical Medicine and Hygiene
Malaria volunteer infection studies (VISs) accelerate new drug and vaccine development. In the induced blood-stage malaria (IBSM) model, volunteers are inoculated with erythrocytes infected with Plasmodium falciparum. Observations of elevated liver e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b4a7bf8dfed4c52ba9341c47a450ed3c
https://pubmed.ncbi.nlm.nih.gov/32314694
https://pubmed.ncbi.nlm.nih.gov/32314694
The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound
Autor:
Martin P. Grobusch, Suzan A. M. Bouwman, Rella Zoleko-Manego, Ghyslain Mombo-Ngoma, Esther K. Schmitt, Katalin Csermak Renner
Publikováno v:
Travel medicine and infectious disease, 36:101765. Elsevier USA
Background Cipargamin (KAE609) is a novel spiroindolone class drug for the treatment of malaria, currently undergoing phase 2 clinical development. This review provides an overview and interpretation of the pre-clinical and clinical data of this poss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f85e5d58dbc4654f82000783cea9f2a
https://pubmed.ncbi.nlm.nih.gov/32561392
https://pubmed.ncbi.nlm.nih.gov/32561392
Autor:
Anne Altmeyer, Nicholas Sauter, Linda Lantwicki, Rosh Dias, Richard Weitzman, John Hohneker, Erik Fink Eriksen, Peter G. Tarassoff, Lynne McGrath, Katalin Csermak-Renner, Leo V. Lacerna
Publikováno v:
Critical Reviews in Oncology/Hematology. 62:148-152
In light of recent reports of osteonecrosis of the jaw (ONJ) in cancer patients whose treatment regimens include an intravenous bisphosphonate, Novartis convened an international advisory board of experts in the fields of oral surgery and pathology,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb264871b20e56b933dd73a6be8020c1
https://doi.org/10.1016/j.critrevonc.2006.12.005
https://doi.org/10.1016/j.critrevonc.2006.12.005